WASHINGTON, DC — The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.“The Biosimilars Council and AAM applauds unanimous Senate passage of the Cornyn-Blumenthal legislation,” said Craig Burton, executive director of the biosimilars council. “Patent thickets are used by brand pharmaceutical companies to maintain high prices and deny patients access to lower-cost medicines. This legislation is a great step in curbing these abuses and will help increase competition and access for biosimilars. We encourage the House to take up this legislation and for Congress to continue working to help lower costs for patients.”
Biosimilars Council applauds patent abuse act
The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.
Latest
Walgreens ramps up assistance for patients and communities ahead of winter storms
In preparation, the retailer is actively deploying resources to ensure uninterrupted access to essential medications and pharmacy services across impacted regions.
Pharma growth quickens as packaging, compliance pressures mount
the pharmaceutical industry has seen mid-single-digit growth recently, expected to continue through 2030.
FMI makes new appointments to Board of Directors
“FMI is proud to welcome new Directors whose perspectives will help guide this change.”
Labor market lags as consumer spending drives U.S. growth
The unemployment rate stays low at 4.4%, indicating what economists call a “no-hire, no-fire” labor market.